CompletedPhase 2NCT01619644
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial
Studying Rubinstein-Taybi syndrome due to 16p13.3 microdeletion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Bordeaux
- Principal Investigator
- Didier LACOMBE, PU-PHUniversity Hospital Bordeaux, France
- Intervention
- sodium valproate(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 6-21 years · All sexes
- Timeline
- 2012 – 2014
Study locations (1)
- University Hospital Bordeaux, France, Bordeaux, France
Collaborators
Fondation Syndrome de Rubinstein-Taybi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01619644 on ClinicalTrials.gov